DrugPatentWatch Information on Approved Drugs and Drug Products

Building Biotechnology: Starting, managing, and understanding
biotechnology companies

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents
To purchase a subscription and access the complete database, visit www.DrugPatentWatch.com

Drug Patent Expirations in November 2008
* Drugs may be covered by multiple patents or regulatory protections

Tradename Applicant Generic Name Patent Number Patent Expiration
ALKERAN Glaxosmithkline melphalan hydrochloride 4,997,651 Nov 18, 2008
BREVIBLOC Baxter Hlthcare Corp esmolol hydrochloride 5,017,609 Nov 21, 2008
BUSPAR Bristol Myers Squibb buspirone hydrochloride 5,015,646 Nov 14, 2008
COVERA-HS Gd Searle Llc verapamil hydrochloride 5,030,456 Nov 7, 2008
DYNACIRC CR Smithkline Beecham isradipine 5,030,456 Nov 7, 2008
NEUROLITE Lantheus Medcl technetium tc-99m bicisate kit 5,279,811 Nov 23, 2008
NEURONTIN Parke Davis gabapentin 4,894,476 Nov 2, 2008
NEURONTIN Pfizer Pharms gabapentin 4,894,476 Nov 2, 2008
NUVIGIL Cephalon armodafinil 4,927,855 Nov 22, 2008
PRELAY Sankyo troglitazone 4,572,912 Nov 9, 2008
REZULIN Pfizer Pharms troglitazone 4,572,912 Nov 9, 2008

SUBSCRIPTIONS

If this newsletter has been forwarded to you and you would like to subscribe, go to http://www.DrugPatentWatch.com/newsletter

If you no longer wish to receive this newsletter, go to http://www.DrugPatentWatch.com/newsletter/unsubscribe.php

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek independent professional advice before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

All trademarks and applicant names are the property of their respective owners or licensors.